Literature DB >> 24063975

Elevated titers of anti-thyroperoxidase antibodies in patients with multiple system atrophy: a pilot study.

Boris Shihman1, Nir Giladi, Margalit Bleiberg, Alina Rosenberg, Amos D Korczyn, Tanya Gurevich.   

Abstract

OBJECTIVES: Multiple system atrophy (MSA) is a neurodegenerative disease characterized by progressive neuronal loss and alpha-synuclein deposition in oligodendroglial cells in the central nervous system. The cause of MSA remains essentially unknown. A cerebellar syndrome was associated with autoimmune thyroid disease in some cases, apparently not related to MSA and was partially responsive to immunomodulatory therapy. PATIENTS AND METHODS: 28 euthyroid patients who fulfilled the diagnostic criteria for probable MSA, 11 with MSA-cerebellar type (MSA-C), 17 with MSA-parkinsonian type (MSA-P), 28 patients with Parkinson's disease (PD) and 26 normal euthyroid controls were tested the for serum levels of anti-thyroperoxidase antibodies (anti-TPO) and anti-thyroglobulin (Anti-TG) antibodies (Ab).
RESULTS: The laboratory results were statistically similar in all three groups, but 3 MSA-C patients had highly elevated anti-TPO Ab titers.
CONCLUSION: We identified the presence of elevated anti-TPO levels in a small subgroup of MSA-C patients but neither in MSA-P or PD patients nor in healthy controls. These findings may suggest an autoimmune etiology in some cases of MSA-C.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antithyroperoxidase antibodies; Autoimmune mechanisms; Cerebellar syndrome; Multiple system atrophy; Parkinson's disease

Mesh:

Substances:

Year:  2013        PMID: 24063975     DOI: 10.1016/j.clineuro.2013.08.013

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  1 in total

1.  Thyroid Dysfunction and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis.

Authors:  Nipith Charoenngam; Thanitsara Rittiphairoj; Ben Ponvilawan; Klaorat Prasongdee
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.